ANI Pharmaceuticals Inc (ANIP) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Total Revenue Chart for ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc (ANIP) revenue for FY2025 was USD 883.4M, a 43.8% change from FY2024. ANI Pharmaceuticals Inc's revenue grew from USD 123.1K in 1998 to USD 883.4M in 2025 (717727.7% over 27 years). Earnings per share moved from USD -18.88 in 2011 to USD -3.05 in 2022. Revenue compound annual growth rate: 5-year CAGR of 33.5%, 10-year CAGR of 27.7%, 20-year CAGR of 50.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$1.66B
Implied Share Price
$72.32
Enterprise Value
$1.94B
Revenue (TTM)
$978.38M
EBITDA
$209.41M
Profit Margin
11.07%
Trailing P/E
15.65
Forward P/E
7.12
Price/Book (MRQ)
2.86
Price/Sales (TTM)
1.70
EV/EBITDA
7.94
EV/Revenue
1.99
Dividend Yield
—
Book Value
$27.87
Free Cash Flow (FY2025)
$150.90M
Free Cash Flow Yield
9.09%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.